BackGD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasOctober 23, 2024Read MoreRevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastomaOctober 2, 2024Read MoreFOXO1 enhances CAR T cell stemness, metabolic fitness and efficacyJuly 3, 2024Read MoreEffective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression…June 14, 2024Read MoreResearch Highlights and TTCI Internal Meeting Part IIIJune 6, 2024Read MorePreclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complexJune 5, 2024Read MoreArtificial Mini Dendritic Cells Boost T Cell-Based Immunotherapy for Ovarian CancerMay 31, 2024Read MoreResearch Highlights and TTCI Internal Meeting Part IIMay 30, 2024Read MoreResearch Highlights and TTCI Internal Meeting Part IMay 27, 2024Read MoreSynthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapiesMay 1, 2024Read MoreNon-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemiaApril 3, 2024Read MoreSynthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor responseFebruary 28, 2024Read MoreOlder PostsNewer Posts
RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastomaOctober 2, 2024Read More
Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression…June 14, 2024Read More
Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complexJune 5, 2024Read More
Artificial Mini Dendritic Cells Boost T Cell-Based Immunotherapy for Ovarian CancerMay 31, 2024Read More
Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapiesMay 1, 2024Read More
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemiaApril 3, 2024Read More
Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor responseFebruary 28, 2024Read More
